Apogee Therapeutics

Today, we reported Q1 2026 financial results and shared an update on corporate highlights and pipeline progress, reflecting the team’s continued focus on strong execution. We’re encouraged by the APEX Phase 2 Part A 52-week results, which exceeded our expectations and further reinforced the potentially best-in-class profile of zumilokibart. Following our successful public equity financing, we have a strong cash position of approximately $1.3 billion, providing runway into 2029 and through our planned BLA filing in AD. https://lnkd.in/eXFBsCWN

You shouldn't have to spend your life avoiding triggers. It's #AsthmaAwarenessMonth. At Apogee, we are working to advance the standard of #asthma care for patients and their loved ones so that their lives can sound better than this. 

We’re hiring an Associate Director, Biostatistics to join us! At Apogee, we’re refusing to stop at “good enough," advancing a pipeline of novel antibody therapies designed to work better and longer for people living with inflammatory and immunologic diseases. In this role you will act as the statistical lead for one or multiple projects, providing technical leadership and statistical support on study design, project planning, conduct and execution of clinical studies, and scientific publications. If you want to contribute to a growing pipeline working to reshape the standard of care in I&I, we’d love to hear from you. Learn more about the open role here. https://lnkd.in/eYXc_qqq

Join us at #AAD2026 tomorrow, Saturday, March 28 at 9 AM MDT as Dr. Emma Guttman presents late-breaking results from the Phase 2 APEX Part A study of zumilokibart (APG777) in #atopicdermatitis. Today is the first day to view ePosters! Details here: https://uniqo.de/aHCsNR Stop by booth #3058 to learn more about how antibody engineering enables evaluation of 12-week and 24-week dosing intervals.

We're pleased to announce the closing of our $403 million follow-on equity financing. These funds will support advancement of our clinical pipeline, including multiple potentially best-in-class I&I therapies. Details here. https://lnkd.in/e_z_4wFz

We are excited to be on site this year at #AAD2026 from March 27-31, presenting late-breaking data from our Phase 2 APEX Part A study of zumilokibart (APG777) in #atopicdermatitis. If you are on the ground in Denver, visit our medical booth #3058 to learn about our approach to antibody optimization and its potential for best-in-class therapeutics. Scroll below for more details. ⬇️

Today, we announced positive 52-week maintenance data from Part A of the Phase 2 APEX clinical trial of zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe #atopicdermatitis. Results demonstrated durable response with both 3- and 6-month dosing, with deepening of response across lesional and itch endpoints. These data support zumilokibart’s potentially differentiated profile, including significantly less frequent dosing than current standard of care. We look forward to further evaluation of zumilokibart in Phase 3 trials expected to initiate later this year. Join our live conference call and webcast at 8:00 a.m. ET this morning for additional details. https://lnkd.in/ezfRHmeJ

Apogee will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis on March 23, 2026. Following the announcement, we will host a conference call and webcast at 8:00 a.m. ET tomorrow morning to discuss the results. Visit the link below to access the live webcast. https://lnkd.in/e_HTqZEG

We’re hiring a non-MD clinical science Director, Clinical Development to join the Apogee team!   In this role, you’ll help advance clinical development biologics designed to reshape the standard of care for people living with I&I diseases. Our programs combine clinically validated mechanisms with advanced antibody engineering to overcome limitations of existing therapies. If you’re excited about building something new in a fast-moving biotech environment and contributing to a growing pipeline in I&I, we’d love to hear from you.    Visit us at booth #3058 during #AAD2026 in Denver to meet members of our team! https://lnkd.in/ekYAayRd

NOW HIRING: MEDICAL DIRECTORS Our clinical development team is growing! As we advance our I&I pipeline, including our lead program zumilokibart (APG777), we're looking for Medical Directors to join our team. If you’re passionate about drug development and bringing better medicines to patients, check out the job link below. This position is primarily remote and includes travel. Stop by the Apogee booth at #AAD2026 in Denver to meet members of our team! https://lnkd.in/eA4bxV8w